USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers
Tyrosine kinase inhibitors (TKIs) including sunitinib and sorafenib remain first-line therapies for advanced renal cell carcinoma (RCC) and lung cancer (LC), but their efficacy is limited by acquired resistance. By characterizing metabolic adaptations in TKI-resistant tumors, we identify ubiquitin-s...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2026-05-01
|
| シリーズ: | Redox Biology |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2213231726000844 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|